In this study, lenalidomide also reduced the proliferation of GL261 cells according to different treatment doses and interaction times in vitro (Figure S3); however, the combination of lenalidomide and anti-PD1 did not reduce the tumor growth, and the role of lenalidomide in supporting immune cells stimulated with peptides was not observed in detail in this study. Here, PDCD1 is linked to neoplasm.